论文部分内容阅读
作者分析了1981年6月-1987年8月在该单位用联合化疗的29例成人原发MDS,中数年龄47.5(18-68)岁,其中RA2例,RAEB7例,RAEBt16例、CMML4例.3-17月后,9例发展成ANLL.20例在MDS期治疗,9例在发展成ANLL后治疗.28例接受红比踪(RBZ)(200mg/m~2/d×3或4)和Ara-c(120-200mg/m~2/d×7或5天)联合化疗,1例接受大剂量Ara-C(3g/m~2/12小时×6天)。巩固治疗用AMSA(90mg/m~2/d,第1天)和Ara-c(120-200mg/m~2/d第1-5天)。随后每周以Ara-c(120-200mg/m~2/,第1-5天)与
The authors analyzed 29 adult primary MDS patients treated with combination chemotherapy from June 1981 to August 1987 at a median age of 47.5 (18-68) years, of whom RA 2, RAEB 7, RAEBt 16 and CMML 4. Three to 17 months later, 9 developed ANLL, 20 were treated in the MDS phase, and 9 were treated with ANLL. 28 received RBZ (200 mg / m 2 / d x 3 or 4) And Ara-C (120-200mg / m ~ 2 / d × 7 or 5 days) combined chemotherapy, and 1 patient received high dose Ara-C (3g / m ~ 2 / 12h × 6d). Consolidation of treatment with AMSA (90 mg / m ~ 2 / d on day 1) and Ara-c (120-200 mg / m ~ 2 / d on day 1-5). Followed by weekly Ara-c (120-200mg / m ~ 2 / day 1-5)